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OBJECTIVES: To evaluate the cost-effectiveness (CE) immunization with 13-Valent 
Pneumococcal Conjugate Vaccine (PCV13) compared with no vaccination and also 
comparing with PCV10, considering direct effects in the Brazilian private market. 
METHODS: A decision tree model was used to estimate the total number of disease 
and disease sequels caused by S. pneumoniae and the clinical outcomes were mortality 
and incidence rates. The vaccination coverage rate was 90% considering a four-dose 
schedule, the pneumococcal disease according to the Brazilian label and the target 
population was a hypothetical birth cohort in Brazil followed 5 years from the Brazil-
ian Private Market Health care System perspective. RESULTS: Considering only direct 
costs and beneﬁts, the program with PCV13 comparing with PCV10 will avoid 60.652 
cases of disease including pneumonia and invasive disease, and also 133.615 saved 
life years. At a current vaccination’s price (PCV13 cost of R$ 198,11 and PCV10 R$ 
150,90) the CE results will be R$ 3.976,00 for life years gained and R$ 8.760,00 for 
disease averted. Considering the same price for PCV13 and PCV10, PCV13 will 
achieve cost-saving results. The program with PCV13 comparing with no vaccination 
will avoid 204.507 cases of disease including AOM, pneumonia and invasive disease, 
and also 162.239 saved life years. The CE results will be R$ 13.974,00 for life years 
gained and R$ 11.086,00 for disease adverted. CONCLUSIONS: The analysis sug-
gests that the PCV13 within the Brazilian private market expected to be very cost-
effective relative to PCV10 and to no vaccination. Considering the same price, PCV13 
comparing to PCV10 may result in reduction of mortality with resultant cost savings 
(R$ 35 Million).
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IMMUNIZATION SCHEDULE IN THE US
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OBJECTIVES: To estimate the cost-effectiveness of the Advisory Committee on Immu-
nization Practices (ACIP) recommended schedule of adult immunizations in the US. 
METHODS: A cost-effectiveness calculator was constructed for the ACIP recom-
mended adult immunization schedule and included the following vaccination strategies 
(ages in years): Inﬂuenza (annually, age 50+), Hepatitis A/B (Hep A/B, college students 
age 18), Human Papillomavirus (HPV, women age 18–26), Pneumococcal Polysac-
charide (PPV, age 50+), Tetanus-Diphtheria acellular Pertussis (Tdap, age 20), Vari-
cella (age 20+), and Zoster (age 60+). Per-person estimates of discounted costs (2008$) 
and quality adjusted life years (QALYs) were derived from existing cost-effectiveness 
studies of target vaccinations vs. no vaccination. Two approaches were taken—cross-
sectional and longitudinal. In the cross-sectional approach, members of a hypothetical 
US-age-weighted cohort were assumed to receive the vaccinations for which they were 
eligible in a single year, lifetime incremental costs and QALYs were summed over the 
cohort, and an aggregate ICER calculated. In the longitudinal approach, incremental 
costs and QALYs from existing studies were applied to a cohort of 18 year-olds at 
the appropriate age for each vaccine; costs and QALYs were discounted to the present, 
summed, and an aggregate incremental cost-effectiveness ratio (ICER) was calculated. 
RESULTS: Estimated ICERs were $7300/QALY and $8000/QALY for the cross-
sectional and longitudinal approaches, respectively. Both approaches are inﬂuenced 
by inclusion of inﬂuenza vaccinations; however excluding inﬂuenza still results in 
cost-effective ICERs (below $30,000/QALY (cross-sectional) and below $20,000/
QALY (longitudinal)). In contrast, removing HPV, Hep A/B, PPV, Tdap, Varicella, or 
Zoster individually from the immunization schedule does not markedly alter the ICER. 
Advancing the cohort starting age from 18 to 65 years decreases the ICER to $5000/
QALY for the longitudinal approach. CONCLUSIONS: Independent of the analytic 
approach, adult immunization according to the current ACIP schedule is cost 
effective.
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OBJECTIVES: To evaluate cost-effectiveness of linezolid (LIN) vs vancomycin (VAN) 
for the empiric treatment of VAP-MRSA in Colombia. METHODS: A decision tree 
(validated by three infectologists, two intensivists) was designed to assess cost-effec-
tiveness of the two medications. The model simulated costs and effectiveness in a 
temporal horizon of 12 weeks, a third-payer perspective was used. Effectiveness and 
outcome measures were deﬁned as life-years gained (LYs). Clinical efﬁcacy and node 
probabilities were obtained by systematic literature review of published clinical trials, 
which estimated direct costs associated with VAP-MRSA treatment (drugs, hospital-
ization, and costs associated with adverse events). Medical costs from 3 major Colom-
bian cities were used; drug costs were taken from a standard costing source. 
Incremental cost per successfully treated patient (ICERs), one and two-way sensitivity 
analyses for key variables were performed for testing model’s robustness. RESULTS: 
Patients treated with LIN experienced the highest outcomes (6.6 LYs) followed by 
VAN (4.2 LYs). Mean cost per patient was lower for LIN (US$3150) compared to 
VAN (US$3400). The C/E Rate was better for LIN (US$474/LYs) compared to VAN 
(US$806/LYs). CONCLUSIONS: Linezolid is cost saving treatment compared to 
vancomycin in empiric treating mechanic ventilation associated pneumonia by meth-
icillin-resistant Staphylococcus aureus in Colombia.
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OBJECTIVES: To evaluate the cost-effectiveness of Pneumococcal Vaccine Polyvalent 
(PPSV23) in adults older than 60 years old in Colombia. METHODS: A systematic-
review was made to estimate the frequency and costs of pneumococcal pneumonia and 
meningitis in Colombia and the clinical course of the diseases. A database of consulta-
tions and hospitalizations in Colombia (RIPS) was searched. DALY’s were calculated 
from these data. Efﬁcacy and effectiveness of the vaccine was extracted from previous 
research. The time horizon of this study was 5 years. An univariate sensitivity analysis 
was made. Costs were expressed in US$ of 2008. RESULTS: 42,475 cases of pneumo-
nia for all causes were estimated for Colombia, which 4,446 (range: 2,395–8,159) are 
pneumococcal pneumonias, with 1290 deaths (range 470–3,134). A number of 474 
cases (range: 329–532) of pneumococcal meningitis are estimated, with 44 deaths 
(range: 34–81). Averted DALY in the base year was 4,262 (4,127 US$ per averted 
DALY), and in the ﬁfth year was 21,187 (543 US$ per averted DALY). In univariate 
analysis, at a cost of US$10 the vaccine resulted in 817 US$ per averted DALY for the 
base case. CONCLUSIONS: In developed countries immunization with PPSV23 is 
recommended in adults older than 60 years and other groups. This study shows that in 
Colombia, a developing country, this vaccine is cost-effective, at a GDP per capita of 
US$8500 in 2008. Despite the results, estimations would be different if the effectiveness 
of the vaccine in this population were signiﬁcatively different than assumed.
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AN INITIAL COST-EFFECTIVENESS ANALYSIS OF THE NEW 13-VALENT 
PNEUMOCOCCAL CONJUGATE VACCINE (PCV-13) VERSUS PCV-7 IN 
THE PUBLIC SECTOR OF HONG KONG
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OBJECTIVES: Local cost-effectiveness studies using local health data have supported 
the long-term health and economic beneﬁts of the PCV-7 due to herd immunity and 
have led to its inclusion in the routine immunization programme for infants in Hong 
Kong since September 2009. PCV-13 is due to be introduced in 2010. The aim of the 
present study is therefore to compare its clinical and economic impacts to those of the 
existing PCV-7 on the whole population of Hong Kong. METHODS: A decision 
analytical model modiﬁed from the recent Prevenar-13 Economic Impact (PREVENT) 
Model (RTI Health Solution) was used for the analysis of the outcomes of vaccination. 
The entire population of Hong Kong of around 7 million was analyzed with infants 
≤ 2 yo receiving PCV-7 vs PCV-13. Population data, incidence rates, serotype cover-
age, disease sequelae, mortality rates, vaccine effectiveness, duration of protection, 
herd effects, utilities, cost of vaccination, direct and indirect costs were adopted from 
local published studies, previous economic assessments of PCV-7 and PCV-13 and 
local government ﬁgures to populate the model. Sensitivity analyses were performed 
to check the robustness of the results. The time horizon was one year and the study 
was performed from a societal perspective. RESULTS: Over a period of 1 year, based 
on an assumption of 85% coverage in infants, our analysis showed for a 4-dose 
regimen of PCV-13 as compared to a 4-dose PCV-7: a gain of 6 life-years and 5 
quality-adjusted-life-years (QALY); an avoidance of 108 related illnesses (including 
bacteraemia, all-cause pneumonia, meningitis and otitis media) and 1 death; cost/
life-year-gained was −US48,044, cost/QALY was −US53,383, and cost/illness avoided 
was −US 2,702. CONCLUSIONS: Based on this initial analysis, our study results 
suggest PCV-13 vaccination dominates PCV-7 in providing protection to the people 
of Hong Kong. Health authority should therefore consider replacing PCV-7 with 
PCV-13 in due course.
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OBJECTIVES: Diabetic foot infection is a frequent complication for diabetes patients 
that lead to high economical costs. The purpose of this study was to develop an eco-
Abstracts A191
nomic model in order to evaluate the cost-effectiveness ratios between ertapenem and 
the patterns of antibiotics routinely used for the treatment of diabetic foot infections at 
the Social Security Mexican Institute (IMSS) from the health care payer’s perspective. 
METHODS: A cost-effectiveness analysis was developed using a Bayesian decision-tree 
model. The model simulates costs and effectiveness outcomes in a 4-week period. The 
comparators were: ertapenem(1 g daily); metronidazole(500 mg every 8 h)/ceftriaxone 
(1 g every 12 h); metronidazole(500 mg every 8 h)/levoﬂoxacin(500 mg every 12 h); 
metronidazole(500 mg every 8 h)/ciproﬂoxacin (500 mg every 12 h). Resource use and 
cost data were obtained from hospital (second level) records of 104 of treated patients. 
Effectiveness measures were the percentage of clinical success without adverse events 
(AE) at the end of the follow-up-period. Effectiveness data and transition probabilities 
were taken from international published literature and were adjusted according to the 
antimicrobial susceptibility identiﬁed locally. The model was calibrated according to 
international pharmacoeconomics guidelines. One-way and probabilistic sensitivity 
analyses were performed using Monte Carlo Simulation second-order approach. 
RESULTS: Patients who received ertapenem experienced 62.7% of clinical success 
without AE, followed by metronidazole/ceftriaxone (23.9%) and metronidazole/levo-
ﬂoxacin (17.8%). Mean cost per patient were lower for ertapenem (US$4306.46) fol-
lowed by metronidazole/ceftriaxone(US$8014.93) and metronidazole/levoﬂoxacin 
(US$8625.11). Based on ICER’s ertapenem resulted as the dominant therapy. Accept-
ability curves showed ertapenem as the most cost-effective therapy closer to 100% 
independently of IMSS willingness to pay. CONCLUSIONS: The results show that in 
México, ertapenem is the most cost-effective antibiotic therapy for diabetic foot infec-
tions. These results should be taken into account by Mexican decision makers for the 
management of this complication in patients with Diabetes Mellitus.
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OBJECTIVES: Case of latent tuberculosis has increased over the years as many from 
developing countries travel to the US. This study compared three CDC recommended 
regimens (Isoniazid, rifampin, and rifampin-pyrazinamide) for latent tuberculosis by 
conducting a cost effectiveness analysis taking into consideration adherence rates and 
incidence of adverse drug events. METHODS: A systematic literature review pertain-
ing to cost-effectiveness studies involving these three regimens from 1990 to 2009 was 
conducted using Pubmed. A decision tree model was developed to infer the most 
cost-effective regimen using data form randomized clinical trails. Cost in the model 
included drug cost, primary physician visit cost, follow up physician visit cost, and 
adverse drug events costs and were obtained from published literature. Rash and 
hepatotoxicity were the adverse events considered in the model as these were highly 
associated with these treatment regimens. Completion rate (adherence to the medica-
tion regimen) was the outcomes evaluated. One-way sensitivity analyses were con-
ducted by varying various costs by 10% to check for the robustness of the model. 
RESULTS: The base-case analysis revealed rifampin-pyrazinamide to be the most 
cost-effective regimen. The one-way sensitivity analysis indicated the results to be 
robust. The total cost for treatment with isoniazid was $1360.53, rifampin was 
$2111.34, and rifampin-pyrazinamid combination was $978.69. The adherence rate 
to isoniazid treatment was 53% as compared to rifampin and rifampin-pyrazinamide 
which was found to be 70% and 81% respectively. Rifampin-pyrazinamide associated 
with hepatotoxicity (4%) as compared to isoniazid (1.5%) and rifampin (3%) still 
proved cost effective. ICER for switching the treatment from rifampin-pyrazinamide 
regimen to isoniazid was $86.87 and to rifampin was $237.02. CONCLUSIONS: 
These analyses based on the data from randomized clinical trial, shows that rifampin-
pyrazinamide was indicated to be the cost effective treatment for patients with latent 
TB, as compared to isoniazid and rifampin alone.
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OBJECTIVES: Invasive Aspergillosis (IA) constitutes the most common cause of infec-
tious pneumonic mortality and represents high economic impact for patients undergo-
ing allogeneic hematopoietic stem cell transplantation and cancer, besides, it is an 
important cause of opportunistic and disseminated respiratory infections in immuno-
compromised patients. Voriconazole (VORI) and amphotericin B deoxycholate (AMB) 
are licensed antifungal therapies for primary treatment of IA, however, costs and 
efﬁcacy of these medications differ. Hypothesis: Voriconazole is cost-effective com-
pared to Amphotericin B for the treatment of IA in immunocompromised patients. 
METHODS: A decision tree (validated by one oncologist and three infectologists) was 
designed to assess cost-effectiveness of the two medications. The model simulated costs 
and effectiveness in a temporal horizon of 14 weeks. Effectiveness and outcome 
measures were deﬁned as rate of survival and life-years gained (LYs) respectively. 
Clinical efﬁcacy and node probabilities were obtained by systematic literature review 
of randomized controlled trials, which estimated direct costs associated with IA treat-
ment (antifungal drugs, hospitalization, and costs associated with adverse events). 
Medical costs from 3 major Colombian cities were used; drug costs were taken from 
a standard costing source. Incremental cost per successfully treated patient (ICERs), 
one and two-way sensitivity analyses (varying clinical success rates and costs of anti-
fungics) were performed for testing model’s robustness RESULTS: Patients treated 
with VORI experienced the highest outcomes (1.20 LYs) followed by AMB (0.68 LYs). 
Mean cost per patient was lower for AMB (US$4829) followed by VORI (US$7078). 
The C/E Rate was better for VORI (US$5896) compared to AMB (US$7036), Based 
on ICERs, VORI was cost-effective compared to AMB (ICER US$ 4374) when the 
willingness to pay threshold is US$8200 and over per patient (1 GDP per capita) 
CONCLUSIONS: Voriconazole represents the cost-effective treatment of choice when 
compared to amphotericin B deoxycholate for Invasive Aspergillosis in immunocom-
promised patients in Colombia.
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OBJECTIVES: To estimate the cost effectiveness of changing from live oral poliovirus 
vaccine to inactivated poliovirus vaccine in Colombia. METHODS: A review of sci-
entiﬁc literature on Vaccine-Associated Paralytic Poliomyelitis in Latin America was 
made. An analysis of Vaccine-Associated Paralytic Poliomyelitis of data from Colom-
bia was also realized. A Markov model was constructed to estimate the cost-effective-
ness of the two strategies in two cohorts of children ranging from birth to 2 years of 
age. The model compared the risks and costs of live oral poliovirus vaccine and 
inactivated poliovirus vaccine in the two cohorts. RESULTS: Between 1988 and 1998 
there were 9 detected cases of Vaccine-Associated Paralytic Poliomyelitis, for a rate 
of 1 per 1.6 millions in the ﬁrst dose, and 1 per 2.5 millions of total administered 
doses. The introduction of the inactivated poliovirus vaccine would prevent 1 case of 
Vaccine-Associated Paralytic Poliomyelitis every two years, and it would prevent 64 
DALY’s in each cohort of vaccinated children. Incremental cost-effectiveness ratio 
would be US$71,062 per DALY averted. CONCLUSIONS: Vaccination with inacti-
vated poliovirus vaccine is not cost-effective even assuming a substantially greater 
incidence of Vaccine-Associated Paralytic Poliomyelitis, this given a GDP per capita 
of US$8,500 in 2008.
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OBJECTIVES: Invasive candidiasis (IC) is associated with increased morbidity and 
mortality of hospitalized patients, as well as in treatment costs, which has a negative 
impact on institutional budgets. Therapeutic programs in which patients are switched 
from intravenous (IV) to oral formulations have the potential of costs reduction regard-
ing IV alone therapies. The purpose of this study was to estimate the economic and 
health consequences of IC treatment in non-neutropenic adult patients using an anti-
fungal sequential strategy, from the Instituto Mexicano del Seguro Social (IMSS) per-
spective. METHODS: A cost–effectiveness analysis was developed using a decision 
tree-model (horizon: 12 weeks). The model estimated length of stay (LOS) associated 
to IV therapies: anidulafungin (reference), ﬂuconazole, caspofungin, voriconazole, 
amphotericin B (AmB) and liposomal amphotericin (LAmB), followed by oral voricon-
azole in respondents. Efﬁcacy and safety data, as well as duration of IV phase associated 
with each therapy were extracted from published clinical trials. Resource use was col-
lected from clinical records (n = 78) at Hospital de Especialidades, Centro Médico 
Nacional “Siglo XXI” (IMSS). Unit costs were obtained from institutional sources and 
expressed in 2009 US$. Probabilistic sensitivity analysis was performed (10,000 Monte 
Carlo iterations) and acceptability curves were constructed. RESULTS: LOS (days) for 
anidulafungin, ﬂuconazole, caspofungin, voriconazole, LAmB and AmB were: 26.2, 
30.4, 27.4, 29.3, 29.8, and 30.2, respectively. Expected costs were US$27,307, 
US$32,053 (+17.4%), US$30,183 (+10.53%), US$29,457 (+8%), US$29,345 (7%) 
and US$32,906 (+21%), respectively. Stay in intensive care unit is approximately 30% 
of LOS. Due to a greater reduction in LOS and a smaller cost than competing alterna-
tives, anidulafungin + oral voriconazole strategy was dominant. Acceptability curves 
showed that, independently of willingness to pay, anidulafungin + oral voriconazole 
exhibits at least 65% probability to be cost-effective regarding competing alternatives. 
CONCLUSIONS: Anidulafungin + oral voriconazole sequential therapy to treat IC in 
non-neutropenic patients would be a cost-saving strategy at IMSS.
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OBJECTIVES: To determine the cost-effectiveness of 13-valent pneumococcal conju-
gate vaccine (PCV13) versus 7-valent pneumococcal conjugate vaccine (PCV7) and 
versus 10-valent pneumococcal conjugate vaccine (PCV10) in preventing pneumococ-
